SHKK(SH:900943)2020-04-24 16:00Financial Performance - Operating revenue fell by 17.82% to CNY 210,023,238.90 year-on-year[6] - Net profit attributable to shareholders decreased by 66.61% to CNY 2,303,120.22 compared to the same period last year[6] - The net cash flow from operating activities was negative at CNY -17,737,668.61, a decrease of 506.08% year-on-year[6] - The company predicts a cumulative net profit decline of approximately 70% compared to the same period last year due to the ongoing impact of the COVID-19 pandemic[13] - The apparel segment experienced a significant reduction in domestic and international orders, leading to decreased foot traffic in physical stores and overall operational performance[13] - The pharmaceutical segment was affected by hospital department suspensions and various medical reform policies, impacting wholesale business[13] - Cash received from sales decreased compared to the same period last year, contributing to reduced revenue and gross profit[15] - Total operating revenue for Q1 2020 was ¥210,023,238.90, a decrease of 17.8% compared to ¥255,562,091.53 in Q1 2019[23] - Net profit for Q1 2020 was ¥2,029,107.17, a decline of 70.7% from ¥6,903,546.90 in Q1 2019[23] - The company reported a comprehensive income total of ¥2,665,818.80 for Q1 2020, significantly lower than ¥27,350,953.01 in Q1 2019, a decrease of 90.2%[23] Assets and Liabilities - Total assets decreased by 4.49% to CNY 993,853,072.76 compared to the end of the previous year[6] - Total current assets as of March 31, 2020, amounted to CNY 498,473,483.24, down from CNY 541,856,147.52 at the end of 2019[17] - Total liabilities decreased from CNY 520,469,182.88 at the end of 2019 to CNY 471,042,832.49 as of March 31, 2020[18] - The company's total liabilities decreased to ¥164,694,528.10 in Q1 2020 from ¥173,377,802.86 in Q4 2019, a reduction of 5.4%[21] - Total equity increased slightly to ¥477,248,784.85 in Q1 2020 from ¥476,663,821.14 in Q4 2019, reflecting a growth of 0.12%[21] Cash Flow - The company's cash and cash equivalents increased to CNY 240,846,936.28 from CNY 231,517,904.83 at the end of 2019[17] - Cash inflow from operating activities decreased to $13.29 million in Q1 2020 from $15.95 million in Q1 2019, a decline of approximately 16.7%[34] - Net cash flow from operating activities improved to -$2.64 million in Q1 2020 compared to -$3.73 million in Q1 2019, showing a reduction in losses[34] - Cash inflow from investment activities significantly increased to $91.25 million in Q1 2020 from $34.03 million in Q1 2019, representing a growth of approximately 168.5%[34] - The net increase in cash and cash equivalents for Q1 2020 was $34.50 million, contrasting with a decrease of $0.71 million in Q1 2019[34] - The ending balance of cash and cash equivalents reached $126.18 million in Q1 2020, compared to $30.14 million in Q1 2019, marking an increase of approximately 318.5%[34] Shareholder Information - The number of shareholders reached 27,716, with the largest shareholder holding 26.51% of the shares[9] Management and Expenses - Financial expenses decreased by 179.00% to CNY -4,014,891.87, indicating improved financial management[10] - The company reported a loss of CNY 2,425,000 from the newly consolidated outpatient department during the reporting period[15] - The company's management expenses decreased to ¥2,011,272.54 in Q1 2020 from ¥3,193,289.58 in Q1 2019, indicating improved cost management[27] - The company incurred financial expenses of -¥4,231,404.84 in Q1 2020, compared to ¥4,912,690.14 in Q1 2019, reflecting a significant reduction in financial costs[27] Investment Income - Investment income surged by 1,819.08% to CNY 839,283.53 compared to the previous period[10] - The investment income for Q1 2020 was ¥1,248,118.61, a notable increase from ¥22,834.36 in Q1 2019[27]